Mibavademab for Amenorrhea

(KYRIAD Trial)

This trial tests an experimental drug, mibavademab, to determine if it can help women with Functional Hypothalamic Amenorrhea (FHA) resume menstruation. FHA occurs when the brain fails to send the correct signals to the ovaries, halting periods. Researchers aim to assess whether mibavademab can improve reproductive hormone levels and evaluate its safety. Women who have not had a period for at least three months and lack other conditions causing missed periods may qualify for this study. As a Phase 2 trial, this research measures mibavademab's effectiveness in an initial, smaller group, allowing participants to contribute to significant findings.

The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the study team or your doctor.

Research shows that mibavademab is under investigation for its safety and effectiveness in treating Functional Hypothalamic Amenorrhea (FHA). Earlier studies tested mibavademab for other conditions, such as generalized lipodystrophy, and found it to be reasonably safe. Mibavademab activates leptin receptors, and patients generally tolerated it well.

Some side effects were reported, mostly mild to moderate, such as minor injection site reactions or mild headaches. Serious side effects were rare in those studies. However, treatments can affect people differently.

Most treatments for amenorrhea, like hormonal therapies, aim to balance hormone levels to restore menstrual cycles. But Mibavademab works differently, targeting specific pathways associated with amenorrhea that aren't addressed by standard hormone treatments. Researchers are excited about Mibavademab because it offers a novel mechanism of action that could provide relief for patients who don't respond well to traditional therapies. With its unique approach, Mibavademab has the potential to open new doors in amenorrhea treatment, offering hope for more personalized and effective care.

Research suggests that mibavademab, which participants in this trial may receive, might help treat Functional Hypothalamic Amenorrhea (FHA) by encouraging the body to produce the hormones needed for ovulation. Previous studies have shown that mibavademab, acting like the hormone leptin, can help balance hormones and improve energy use in the body. Early research also found that this treatment might help manage body weight and control blood sugar levels, both important for reproductive health. While more studies are needed to confirm these benefits specifically for FHA, mibavademab shows promise in addressing the hormonal imbalances related to this condition.¹⁵⁶⁷⁸